Chronic Immune-Mediated Diarrhea and Colitis Associated With Prolonged Survival in Patients Treated With ICIs
The immune-related AE, immune-mediated diarrhea and colitis, can have a limited course or may exist for long-term periods.
All articles by Susan Moench, PhD, PA-C
Initiative Facilitates Integration of Cancer Rehabilitation Into GI Cancer Care
Investigators describe the steps taken to improve clinician referrals to the facility’s outpatient rehabilitation program for patients with GI cancers.
Rectal Cancer Recurrence Risk Followed With “Watch and Wait”
The “watch and wait” approach is characterized by close surveillance without surgery in patients with rectal cancer who achieve a clinical CR following neoadjuvant CRT.
More Support for “Watch-and-Wait” Approach in Some With Resectable Rectal Cancer
Suspected local disease regrowth was seen in 23% of patients with rectal cancer observed following a near or complete clinical response to neoadjuvant therapy.
Multiple Factors Linked to Hospital Readmission Following Pancreatectomy
Results of this study showed no improvement in the rate of 30-day hospital readmission for patients with cancer undergoing pancreatectomy between 2005 and 2011.
Sociodemographic Factors Influenced Survival in Young Adults With Colorectal Cancer
In this study, a young adult was defined as an individual who was 40 years or younger.
No Local Control or OS Benefit Seen With RT Dose Escalation in Inoperable Esophageal Cancer
In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.
Study Finds Atezolizumab Plus Bevacizumab Prolongs Maintenance of QoL Compared With Sorafenib in Certain Patients With HCC
In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.
Avelumab Maintenance: No OS Benefit vs Continued Chemotherapy in HER2-Negative Gastrointestinal Cancers
Fewer treatment-related grade 3 or higher adverse events were reported in the avelumab arm compared with the chemotherapy arm.
Longer Maintenance of QoL in BRAF V600E-Mutant Metastatic Colorectal Cancer With Triplet Regimen vs an Irinotecan-Based Regimen
The randomized, phase 3 BEACON CRC trial was a 3-arm study conducted in patients with pretreated metastatic CRC characterized by a BRAF V600E mutation.
- Loading...
Loading...
Next post in Colorectal neoplasia
Loading... 
Loading...